Technology
Health
Medical

BioLife Solutions

$17.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.87 (-4.63%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BLFS and other stocks, options, ETFs, and crypto commission-free!

About

BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. Read More The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.

Employees
54
Headquarters
Bothell, Washington
Founded
1998
Market Cap
348.32M
Price-Earnings Ratio
144.63
Dividend Yield
0.00
Average Volume
231.61K
High Today
$19.15
Low Today
$17.80
Open Price
$18.81
Volume
84.18K
52 Week High
$26.35
52 Week Low
$4.85

Collections

Technology
Health
Medical
Advertising and Marketing
Media
Business Services
US
North America

News

Simply Wall StMar 25

Why We’re Not Keen On BioLife Solutions, Inc.’s (NASDAQ:BLFS) 8.4% Return On Capital

Today we are going to look at BioLife Solutions, Inc. (NASDAQ:BLFS) to see whether it might be an attractive investment prospect. Specifically, we’ll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. Firstly, we’ll go over how we calculate ROCE. Then we’ll compare its ROCE to similar companies. Finally, we’ll look at how its current liabilities affect its ROCE. Understanding Return On Capi...

104
Guru FocusMar 15

BioLife Solutions Inc (BLFS) Files 10-K for the Fiscal Year Ended on December 31, 2018

BioLife Solutions Inc (NASDAQ:BLFS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. BioLife Solutions Inc manufactures proprietary and generic cGMP biopreservation media products, generic formulations of blood stem cell freezing media products, custom product formulation packaging services and contract aseptic manufacturing formulation.

141
The Motley FoolMar 14

Biolife Solutions Inc (BLFS) Q4 2018 Earnings Conference Call Transcript

Biolife Solutions Inc (NASDAQ:BLFS) Q4 2018 Earnings Conference Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the BioLife Solutions Fourth Quarter and Full Year 2018 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. (Operator Instructions) As a reminder, this confe...

88

Earnings

-$0.06
-$0.02
$0.01
$0.05
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
$0.05 per share
Actual
$0.04 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.